Royal Bank of Canada
TRDA icon

Royal Bank of Canada’s Entrada Therapeutics TRDA Stock Holding History

Royal Bank of Canada’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Sell
25
-962
-97% -$11K ﹤0.01% 7701
2025
Q4 		$11K Sell
987
-41,152
-98% -$347K ﹤0.01% 6381
2025
Q3 		$245K Buy
42,139
+22,797
+118% +$133K ﹤0.01% 4956
2025
Q2 		$130K Buy
19,342
+11,034
+133% +$88.8K ﹤0.01% 5464
2025
Q1 		$75K Sell
8,308
-3,491
-30% -$43.5K ﹤0.01% 5384
2024
Q4 		$204K Sell
11,799
-3,401
-22% -$61.6K ﹤0.01% 4803
2024
Q3 		$243K Buy
15,200
+6,778
+80% +$107K ﹤0.01% 4659
2024
Q2 		$120K Buy
8,422
+7,278
+636% +$103K ﹤0.01% 5156
2024
Q1 		$16K Sell
1,144
-5,941
-84% -$84K ﹤0.01% 6019
2023
Q4 		$107K Buy
7,085
+3,361
+90% +$49.8K ﹤0.01% 5583
2023
Q3 		$59K Buy
3,724
+1,491
+67% +$23.5K ﹤0.01% 5701
2023
Q2 		$34K Buy
+2,233
New +$30.8K ﹤0.01% 5962
2023
Q1 		– Sell
-28
Closed – – 7480
2022
Q4 		$0 Buy
+28
New +$491 ﹤0.01% 7727
2022
Q2 		– Sell
-646
Closed -$6K – 7719
2022
Q1 		$6K Sell
646
-1,217
-65% -$13K ﹤0.01% 7201
2021
Q4 		$32K Buy
+1,863
New +$45.2K ﹤0.01% 6597

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada's TRDA Position: Q1 2026 in Review

Royal Bank of Canada reduced its Entrada Therapeutics (TRDA) stake by 97% in Q1 2026, selling an estimated $11K and leaving 25 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7701.

Royal Bank of Canada first reported a position in TRDA in Q4 2021 and has held it in 15 quarters since. The position peaked at $245K in Q3 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Royal Bank of Canada held 25 shares of Entrada Therapeutics worth $0 as of Q1 2026.
  • Royal Bank of Canada sold 962 Entrada Therapeutics shares in Q1 2026, an estimated $11K.
  • Entrada Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7701 holding.
  • Royal Bank of Canada first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • Royal Bank of Canada's Entrada Therapeutics position peaked at $245K in Q3 2025.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.